Rockwell Automation vs State Street SPDR S&P Biotech ETF — how do they compare? Rockwell Automation trades at $466.05 (market cap $51.04B), while State Street SPDR S&P Biotech ETF trades at $154.4. The key difference: Rockwell Automation pays a 1.2% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| ROK | XBI | |
|---|---|---|
Market Cap | $51.04B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $495.08 | $164.28 |
52-Week Low | $328.67 | $85.16 |
Enterprise Value | $54.67B | — |
Dividend Yield | 1.2% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →